Nandita Khera|Yu Hui H. Chang|Shahrukh K. Hashmi|James L. Slack|Timothy J. Beebe|Vivek Roy|Pierre Noël|Veena Fauble|Lisa Z. Sproat|Jon C. Tilburt|José F. Leis|Joseph M?khael
Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation
Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic|Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic in Florida|Mayo Clinic in Florida|Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic|Winneshiek Medical Center|Mayo Clinic in Florida|Winneshiek Medical Center|Mayo Clinic in Florida|Winneshiek Medical Center
although allogeneic hematopoietic cell transplantation hct expensive treatment hematological disorders little known financial consequences patients undergo procedure analyzed factors associated financial burden impact health behaviors allogeneic hct recipients questionnaire retrospectively mailed 482 patients underwent allogeneic hct january 2006 june 2012 mayo clinic collect information regarding current financial concerns household income employment insurance outofpocket expenses health functional status multivariable logistic regression analysis identified factors associated financial burden treatment nonadherence 268 respondents 56 response rate 73 reported sickness hurt financially patients insurance information available missing n 13 insured fortyseven percent respondents experienced financial burden household income decreased 50 sellingmortgaging home withdrawing money retirement accounts three percent declared bankruptcy younger age poor current mental physical functioning increased likelihood financial burden thirtyfive percent patients reported deleterious health behaviors financial constraints patients likely younger lower education longer time since hct employed decreased likelihood experiencing financial burden treatment nonadherence due concern costs significant proportion allogeneic hct survivors experience financial hardship despite insurance coverage future research investigate potential interventions help atrisk patients prevent adverse financial outcomes lifesaving procedure